Oxolinic acid: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) Created page with "{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 384087896 | IUPAC_name = 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-''g'']quinoline- 7-carboxyl..." |
m Protected "Oxolinic acid": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
| verifiedrevid = 384087896 | | verifiedrevid = 384087896 | ||
| IUPAC_name = 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-''g'']quinoline- 7-carboxylic acid | | IUPAC_name = 5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-''g'']quinoline- 7-carboxylic acid | ||
| image = Oxolinic acid.png | | image =Oxolinic acid.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| Line 46: | Line 46: | ||
| molecular_weight = 261.23 g/mol | | molecular_weight = 261.23 g/mol | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Oxolinic acid''' is a [[quinolone]] [[antibiotic]] developed in Japan in the 1970s.<ref>JP Patent 49138244</ref><ref name="pmid384788">{{cite journal |author=Gleckman R, Alvarez S, Joubert DW, Matthews SJ |title=Drug therapy reviews: oxolinic acid |journal=American Journal of Hospital Pharmacy |volume=36 |issue=8 |pages=1077–9 |year=1979 |month=August |pmid=384788 |doi= |url= }}</ref> Dosages 12–20 mg/kg orally administered for five to ten days. The antibiotic works by inhibiting the enzyme [[DNA gyrase]]. It also acts as a [[dopamine reuptake inhibitor]] and has stimulant effects in mice.<ref name="pmid9928913">{{cite journal |author=Garcia de Mateos-Verchere J, Vaugeois JM, Naudin B, Costentin J |title=Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor |journal=European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology |volume=8 |issue=4 |pages=255–9 |year=1998 |month=December |pmid=9928913 |doi= 10.1016/S0924-977X(97)00083-7|url=http://linkinghub.elsevier.com/retrieve/pii/S0924-977X(97)00083-7}}</ref> | '''Oxolinic acid''' is a [[quinolone]] [[antibiotic]] developed in Japan in the 1970s.<ref>JP Patent 49138244</ref><ref name="pmid384788">{{cite journal |author=Gleckman R, Alvarez S, Joubert DW, Matthews SJ |title=Drug therapy reviews: oxolinic acid |journal=American Journal of Hospital Pharmacy |volume=36 |issue=8 |pages=1077–9 |year=1979 |month=August |pmid=384788 |doi= |url= }}</ref> Dosages 12–20 mg/kg orally administered for five to ten days. The antibiotic works by inhibiting the enzyme [[DNA gyrase]]. It also acts as a [[dopamine reuptake inhibitor]] and has stimulant effects in mice.<ref name="pmid9928913">{{cite journal |author=Garcia de Mateos-Verchere J, Vaugeois JM, Naudin B, Costentin J |title=Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor |journal=European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology |volume=8 |issue=4 |pages=255–9 |year=1998 |month=December |pmid=9928913 |doi= 10.1016/S0924-977X(97)00083-7|url=http://linkinghub.elsevier.com/retrieve/pii/S0924-977X(97)00083-7}}</ref> | ||
==Category== | |||
==Brand Names== | |||
==Mechanism of Action== | |||
==See also== | ==See also== | ||
* [[Fluoroquinolone]] | * [[Fluoroquinolone]] | ||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
[[Category:Antibiotics]] | |||
[[Category:Drug]] | |||
Latest revision as of 16:52, 20 August 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C13H11NO5 |
| Molar mass | 261.23 g/mol |
  (what is this?) (verify) | |
|
WikiDoc Resources for Oxolinic acid |
|
Articles |
|---|
|
Most recent articles on Oxolinic acid Most cited articles on Oxolinic acid |
|
Media |
|
Powerpoint slides on Oxolinic acid |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Oxolinic acid at Clinical Trials.gov Trial results on Oxolinic acid Clinical Trials on Oxolinic acid at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Oxolinic acid NICE Guidance on Oxolinic acid
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Oxolinic acid Discussion groups on Oxolinic acid Patient Handouts on Oxolinic acid Directions to Hospitals Treating Oxolinic acid Risk calculators and risk factors for Oxolinic acid
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Oxolinic acid |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oxolinic acid is a quinolone antibiotic developed in Japan in the 1970s.[1][2] Dosages 12–20 mg/kg orally administered for five to ten days. The antibiotic works by inhibiting the enzyme DNA gyrase. It also acts as a dopamine reuptake inhibitor and has stimulant effects in mice.[3]
Category
Brand Names
Mechanism of Action
See also
References
- ↑ JP Patent 49138244
- ↑ Gleckman R, Alvarez S, Joubert DW, Matthews SJ (1979). "Drug therapy reviews: oxolinic acid". American Journal of Hospital Pharmacy. 36 (8): 1077–9. PMID 384788. Unknown parameter
|month=ignored (help) - ↑ Garcia de Mateos-Verchere J, Vaugeois JM, Naudin B, Costentin J (1998). "Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 8 (4): 255–9. doi:10.1016/S0924-977X(97)00083-7. PMID 9928913. Unknown parameter
|month=ignored (help)
Categories:
- Pages with script errors
- Pages with citations using unsupported parameters
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Articles with changed KEGG identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Antibiotics
- Drug